According to CRISPR Therapeutics's latest financial reports the company's current EPS (TTM) is -ยฃ4.62. In 2025 the company made an earnings per share (EPS) of -ยฃ4.84 a decrease over its 2024 EPS that were of -ยฃ3.24.